[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100546956":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":41,"responsibleParty":57,"collaborators":29,"id":59,"slug":29,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":62,"acronym":63,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":29,"enrollmentInfo":67,"targetDuration":29,"studyType":70,"phases":71,"briefSummary":73,"conditions":74,"keywords":78,"overallStatus":44,"whyStopped":29,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"University of California, San Francisco","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Perampanel","ACTIVE_COMPARATOR","Perampanel oral load of 24mg upon randomization followed by 8mg oral dose daily for four more days (second dose one day after load and total treatment duration is 5 days)",[13],"Drug: Perampanel",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Placebo oral load upon randomization followed by daily placebo oral dose administration for four more days (second dose one day after load and total placebo administration duration is 5 days)",[19],"Drug: Placebo",[21,27],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Perampanel is a non-competitive AMPA glutamate receptor antagonist.",[9],[26],"Fycompa",{"type":22,"name":15,"description":15,"armGroupLabels":28,"otherNames":29},[15],null,[31],{"name":32,"affiliation":5,"role":33},"Edilberto Amorim, MD","PRINCIPAL_INVESTIGATOR",[35,39],{"name":32,"role":36,"phone":37,"phoneExt":29,"email":38},"CONTACT","628-206-3203","prosperstudy@ucsf.edu",{"name":40,"role":36,"phone":29,"phoneExt":29,"email":38},"Kevin Bao, BA",[42],{"facility":43,"status":44,"city":45,"state":46,"zip":47,"country":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"Zuckerberg San Francisco General Hospital","RECRUITING","San Francisco","California","94110","United States",{"type":50,"coordinates":51},"Point",[52,53],-122.41942,37.77493,{"lat":53,"lon":52},[56],{"name":32,"role":36,"phone":29,"phoneExt":29,"email":29},{"type":58,"investigatorFullName":29,"investigatorTitle":29,"investigatorAffiliation":29,"oldNameTitle":29,"oldOrganization":29},"SPONSOR","100546956",false,"NCT06401707","PeRampanel fOr Status ePilEpticus pRophylaxis Post-cardiac Arrest","PROSPER","Inclusion Criteria:\n\n* Age ≥18 years old\n* Non-traumatic, out-of-hospital cardiac arrest\n* Comatose on admission - defined as not following commands\n* Return of spontaneous circulation (ROSC) within less than 45 minutes from the time of cardiac arrest (defined as the time of 911 or EMS (emergency medical services) witnessed arrest)\n* Admission to the intensive care unit at Zuckerberg San Francisco General Hospital\n\nExclusion Criteria:\n\n* Acute cerebral hemorrhage or infarction\n* Pregnancy\n* Prisoner\n* Severe kidney function impairment with creatinine clearance inferior to 30 ml\u002Fmin\n* Severe liver impairment with liver function tests five times above the upper limit of normal\n* Electrographic or electroclinical seizures diagnosis using American Clinical Neurophysiology criteria confirmed by an epileptologist after cardiac arrest","ALL","18 Years",{"count":68,"type":69},52,"ESTIMATED","INTERVENTIONAL",[72],"PHASE2","Brain injury is the main cause of death and disability for patients surviving cardiac arrest resuscitation and seizures are diagnosed in up to a third of these patients. The investigators are proposing a pilot randomized placebo-controlled clinical trial to evaluate the safety and feasibility of perampanel use for post-cardiac arrest status epilepticus (PCARSE) prevention after cardiac arrest.",[75,76,77],"Heart Arrest","Seizures","Status Epilepticus",[79,80,81,82],"heart arrest","seizure","status epilepticus","prophylaxis","2025-07-02",{"date":85,"type":86},"2025-07-08","ACTUAL",{"date":88,"type":86},"2024-05-20",{"date":90,"type":69},"2026-10-20",{"name":5,"class":6},1]